Abstract
Materials and methods: We report a retrospective series of 120 patients treated for recurrent malignant gliomas with bevacizumab alone 2013-2018.There are 120 patients (pts) including 60 women and 80 Men with a sex ratio of 1.2. Results: There are 120 patients (pts) including 60 women and 80 Men with a sex ratio of 1.2. All patients had a surgery. the majority had a large or subtotal excision. 80 pts received Stupp protocole and 40 pts a radiotherapy alone. The reccurence was treated with Bevacizumab alone, 3 pts had a Complete Response, 40 Partial Response, 30 stable response and 45 pts a progression. We report a good tolerance, one pts had a proteinurie grade 3, one grade 1, one patient had a moderate high Blood Pressure, and the last one had a hematuria. Conclusion: Young age, good GE and quality of surgical excision are predictive factors for a good prognosis. Bevacizumab remains the recommended drug for recurrent glioblastomas with good tolerance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
